STAT

Opinion: ‘Meticulous’ study shows that value-based care works

The positive, long-term results of the Alternative Quality Contract model should signal to public and private payers in red and blue states that they should continue on the path to…

Health care is a deeply partisan issue, as the presidential campaign makes clear every day. Yet beneath the bitter debates and far from the daily headlines, Republicans and Democrats have quietly come to agree on one reform with far-reaching consequences: transforming our century-old system for paying doctors for the care they provide from one based on fee-for-service visits, tests, and hospital admissions to one based on quality of care, health outcomes, and patient satisfaction, otherwise known as value-based care.

At the federal level, top Trump administration health officials are strong advocates for value-based payment initiatives that originated during the Obama administration. Hundreds of that care for millions of patients are tying payments to quality

You’re reading a preview, subscribe to read more.

More from STAT

STAT1 min readIntelligence (AI) & Semantics
STAT+: Q&A: How The FDA Is Approaching AI In Clinical Trials And Drug Development
The FDA's Tala Fakhouri discusses the agency's approach to the regulation of AI in clinical trials in a new interview.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Pfizer Struggles With Starboard, Lilly Going After Compounders, And More
Two former Pfizer executives said they will not be involved with activist investor Starboard Value
STAT1 min read
Opinion: STAT+: Traditional Randomized Trials Don’t Work For Ultra-rare Diseases Like Barth Syndrome
Opinion: An upcoming FDA ad comm on a treatment for the ultra rare Barth syndrome can’t use the normal measuring sticks for success.

Related